CN102204930B - 用于治疗视网膜变性病的改良模式 - Google Patents
用于治疗视网膜变性病的改良模式 Download PDFInfo
- Publication number
- CN102204930B CN102204930B CN201110132307.3A CN201110132307A CN102204930B CN 102204930 B CN102204930 B CN 102204930B CN 201110132307 A CN201110132307 A CN 201110132307A CN 102204930 B CN102204930 B CN 102204930B
- Authority
- CN
- China
- Prior art keywords
- cell
- rpe
- coloured
- hes
- substratum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000001525 retina Anatomy 0.000 title description 23
- 238000011282 treatment Methods 0.000 title description 16
- 208000015122 neurodegenerative disease Diseases 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims abstract description 321
- 238000000034 method Methods 0.000 claims abstract description 56
- 210000000130 stem cell Anatomy 0.000 claims description 34
- 239000000049 pigment Substances 0.000 claims description 26
- 230000004069 differentiation Effects 0.000 claims description 21
- 210000002919 epithelial cell Anatomy 0.000 claims description 20
- 210000001161 mammalian embryo Anatomy 0.000 claims description 19
- 238000000926 separation method Methods 0.000 claims description 10
- 101000729271 Homo sapiens Retinoid isomerohydrolase Proteins 0.000 claims description 9
- 102100031176 Retinoid isomerohydrolase Human genes 0.000 claims description 9
- 108010058237 plasma protein fraction Proteins 0.000 claims description 9
- 229940002993 plasmanate Drugs 0.000 claims description 9
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 8
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 8
- 230000002269 spontaneous effect Effects 0.000 claims description 6
- 102000018832 Cytochromes Human genes 0.000 claims description 5
- 108010052832 Cytochromes Proteins 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 claims description 4
- 229930182555 Penicillin Natural products 0.000 claims description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 4
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 229940049954 penicillin Drugs 0.000 claims description 4
- -1 Streptomycin sulphates Chemical class 0.000 claims description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 3
- 101000835745 Homo sapiens Teratocarcinoma-derived growth factor 1 Proteins 0.000 claims description 2
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 claims description 2
- 102100026404 Teratocarcinoma-derived growth factor 1 Human genes 0.000 claims description 2
- 101001078886 Homo sapiens Retinaldehyde-binding protein 1 Proteins 0.000 claims 2
- 206010020880 Hypertrophy Diseases 0.000 claims 2
- 102100028001 Retinaldehyde-binding protein 1 Human genes 0.000 claims 2
- 238000011534 incubation Methods 0.000 claims 2
- 108090000102 pigment epithelium-derived factor Proteins 0.000 claims 2
- 229960005322 streptomycin Drugs 0.000 claims 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims 2
- 244000309466 calf Species 0.000 claims 1
- 235000020776 essential amino acid Nutrition 0.000 claims 1
- 239000003797 essential amino acid Substances 0.000 claims 1
- 210000001671 embryonic stem cell Anatomy 0.000 abstract description 54
- 238000002560 therapeutic procedure Methods 0.000 abstract description 9
- 201000007737 Retinal degeneration Diseases 0.000 abstract description 5
- 230000004258 retinal degeneration Effects 0.000 abstract description 5
- 210000001164 retinal progenitor cell Anatomy 0.000 abstract description 3
- 239000000790 retinal pigment Substances 0.000 abstract description 2
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 212
- 108090000623 proteins and genes Proteins 0.000 description 38
- 210000000981 epithelium Anatomy 0.000 description 26
- 102000007354 PAX6 Transcription Factor Human genes 0.000 description 21
- 239000010410 layer Substances 0.000 description 21
- 101150081664 PAX6 gene Proteins 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 19
- 101150087532 mitF gene Proteins 0.000 description 18
- 230000008859 change Effects 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 15
- 210000001508 eye Anatomy 0.000 description 15
- 230000006870 function Effects 0.000 description 15
- 241000282472 Canis lupus familiaris Species 0.000 description 14
- 235000020945 retinal Nutrition 0.000 description 14
- 230000002207 retinal effect Effects 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 101000713575 Homo sapiens Tubulin beta-3 chain Proteins 0.000 description 10
- 101100518992 Mus musculus Pax2 gene Proteins 0.000 description 10
- 208000017442 Retinal disease Diseases 0.000 description 10
- 102100036790 Tubulin beta-3 chain Human genes 0.000 description 10
- 206010064930 age-related macular degeneration Diseases 0.000 description 10
- 230000000007 visual effect Effects 0.000 description 10
- 206010038923 Retinopathy Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 208000002780 macular degeneration Diseases 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 210000002459 blastocyst Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 230000004438 eyesight Effects 0.000 description 8
- 230000007774 longterm Effects 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 7
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 7
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 7
- 210000001109 blastomere Anatomy 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 235000019155 vitamin A Nutrition 0.000 description 7
- 239000011719 vitamin A Substances 0.000 description 7
- 229940045997 vitamin a Drugs 0.000 description 7
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 6
- 208000027089 Parkinsonian disease Diseases 0.000 description 6
- 206010034010 Parkinsonism Diseases 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 210000000554 iris Anatomy 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 210000005157 neural retina Anatomy 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 230000003068 static effect Effects 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 206010003694 Atrophy Diseases 0.000 description 5
- 210000000411 amacrine cell Anatomy 0.000 description 5
- 230000037444 atrophy Effects 0.000 description 5
- 238000002659 cell therapy Methods 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000012797 qualification Methods 0.000 description 5
- 239000011604 retinal Substances 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 5
- 101100351026 Drosophila melanogaster ey gene Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 206010060766 Heteroplasia Diseases 0.000 description 4
- 206010029113 Neovascularisation Diseases 0.000 description 4
- 108010019160 Pancreatin Proteins 0.000 description 4
- 206010043276 Teratoma Diseases 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 210000002189 macula lutea Anatomy 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000003147 molecular marker Substances 0.000 description 4
- 229940055695 pancreatin Drugs 0.000 description 4
- 210000000608 photoreceptor cell Anatomy 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 3
- 108700039887 Essential Genes Proteins 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 208000003098 Ganglion Cysts Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 102000013275 Somatomedins Human genes 0.000 description 3
- 208000005400 Synovial Cyst Diseases 0.000 description 3
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000004373 eye development Effects 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000012239 gene modification Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000005017 genetic modification Effects 0.000 description 3
- 235000013617 genetically modified food Nutrition 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 210000003574 melanophore Anatomy 0.000 description 3
- 238000002715 modification method Methods 0.000 description 3
- 210000000472 morula Anatomy 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 210000000287 oocyte Anatomy 0.000 description 3
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102100032982 CCR4-NOT transcription complex subunit 9 Human genes 0.000 description 2
- 101150032562 CNOT9 gene Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 208000033825 Chorioretinal atrophy Diseases 0.000 description 2
- 206010008790 Choroidal rupture Diseases 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 241000201966 Goura Species 0.000 description 2
- 101001073422 Homo sapiens Pigment epithelium-derived factor Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101100350582 Mus musculus Otx2 gene Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108010032788 PAX6 Transcription Factor Proteins 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 2
- 206010038848 Retinal detachment Diseases 0.000 description 2
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 2
- 206010038934 Retinopathy proliferative Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 102000040739 Secretory proteins Human genes 0.000 description 2
- 108091058545 Secretory proteins Proteins 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 108010017842 Telomerase Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000003161 choroid Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 210000002308 embryonic cell Anatomy 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 238000002647 laser therapy Methods 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000005155 neural progenitor cell Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000008186 parthenogenesis Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 150000003726 retinal derivatives Chemical class 0.000 description 2
- 230000004264 retinal detachment Effects 0.000 description 2
- 210000000880 retinal rod photoreceptor cell Anatomy 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 101150051888 vsx2 gene Proteins 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000005598 Angioid Streaks Diseases 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 102100034613 Annexin A2 Human genes 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 101150061927 BMP2 gene Proteins 0.000 description 1
- 102000012304 Bestrophin Human genes 0.000 description 1
- 108050002823 Bestrophin Proteins 0.000 description 1
- 102100022794 Bestrophin-1 Human genes 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010005176 Blindness congenital Diseases 0.000 description 1
- 241000252229 Carassius auratus Species 0.000 description 1
- 208000008515 Choroidal sclerosis Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 201000001353 Doyne honeycomb retinal dystrophy Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 208000037312 Familial drusen Diseases 0.000 description 1
- 101710145505 Fiber protein Proteins 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241000288105 Grus Species 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 101000903449 Homo sapiens Bestrophin-1 Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- 101500028890 Mus musculus Neurotensin Proteins 0.000 description 1
- 102000008730 Nestin Human genes 0.000 description 1
- 108010088225 Nestin Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010073286 Pathologic myopia Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 230000010748 Photoabsorption Effects 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000014139 Retinal vascular disease Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 101710104507 Retinochrome Proteins 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 208000027073 Stargardt disease Diseases 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- SBCVJZHHHVYKNM-UHFFFAOYSA-M [2-[bis(2-tetradecanoyloxyethyl)amino]-2-oxoethyl]-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCC(=O)OCCN(C(=O)C[N+](C)(C)CCO)CCOC(=O)CCCCCCCCCCCCC SBCVJZHHHVYKNM-UHFFFAOYSA-M 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000011717 all-trans-retinol Substances 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003322 aneuploid effect Effects 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 230000003540 anti-differentiation Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000003570 biosynthesizing effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 101150067309 bmp4 gene Proteins 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000005314 correlation function Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 230000003450 growing effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 210000002287 horizontal cell Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- HVGQWHMSVYODLJ-GFCCVEGCSA-N melanochrome Natural products CC1(C)Oc2cc3OC(=CC(=O)c3c(O)c2C[C@H]1O)CO HVGQWHMSVYODLJ-GFCCVEGCSA-N 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 230000037345 metabolism of vitamins Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000005055 nestin Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002399 phagocytotic effect Effects 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001243 pseudopodia Anatomy 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000004491 retinal development Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012144 step-by-step procedure Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/062—Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/33—Insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Acoustics & Sound (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53896404P | 2004-01-23 | 2004-01-23 | |
| US60/538,964 | 2004-01-23 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2005800073590A Division CN1968608B (zh) | 2004-01-23 | 2005-01-24 | 用于治疗视网膜变性病的改良模式 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102204930A CN102204930A (zh) | 2011-10-05 |
| CN102204930B true CN102204930B (zh) | 2014-12-03 |
Family
ID=34807248
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410645051.XA Pending CN104434979A (zh) | 2004-01-23 | 2005-01-24 | 用于治疗视网膜变性病的改良模式 |
| CN2005800073590A Expired - Lifetime CN1968608B (zh) | 2004-01-23 | 2005-01-24 | 用于治疗视网膜变性病的改良模式 |
| CN201110132307.3A Expired - Lifetime CN102204930B (zh) | 2004-01-23 | 2005-01-24 | 用于治疗视网膜变性病的改良模式 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410645051.XA Pending CN104434979A (zh) | 2004-01-23 | 2005-01-24 | 用于治疗视网膜变性病的改良模式 |
| CN2005800073590A Expired - Lifetime CN1968608B (zh) | 2004-01-23 | 2005-01-24 | 用于治疗视网膜变性病的改良模式 |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US7736896B2 (enExample) |
| EP (8) | EP2929782A1 (enExample) |
| JP (10) | JP2007522131A (enExample) |
| KR (3) | KR101398356B1 (enExample) |
| CN (3) | CN104434979A (enExample) |
| AU (6) | AU2005207042B2 (enExample) |
| BR (1) | BRPI0507074A (enExample) |
| CA (2) | CA2555370C (enExample) |
| ES (1) | ES2721174T3 (enExample) |
| HK (2) | HK1216068A1 (enExample) |
| IL (3) | IL177015B (enExample) |
| MX (4) | MX375061B (enExample) |
| NZ (1) | NZ548929A (enExample) |
| SG (4) | SG10201912182UA (enExample) |
| WO (1) | WO2005070011A2 (enExample) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8043614B2 (en) | 2004-03-09 | 2011-10-25 | Ahlfors Jan-Eric W | Autogenic living scaffolds and living tissue matrices: methods and uses thereof |
| US7794704B2 (en) | 2004-01-23 | 2010-09-14 | Advanced Cell Technology, Inc. | Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration |
| EP2929782A1 (en) | 2004-01-23 | 2015-10-14 | Ocata Therapeutics, Inc. | Improved modalities for the treatment of degenerative diseases of the retina |
| US7893315B2 (en) | 2004-11-04 | 2011-02-22 | Advanced Cell Technology, Inc. | Derivation of embryonic stem cells and embryo-derived cells |
| US7838727B2 (en) | 2004-11-04 | 2010-11-23 | Advanced Cell Technology, Inc. | Derivation of embryonic stem cells |
| CN1966080B (zh) * | 2005-11-17 | 2011-06-08 | 李凌松 | 一种治疗老年痴呆症、帕金森病的神经干细胞注射液 |
| US7541186B2 (en) * | 2006-02-22 | 2009-06-02 | University Of Washington | Method of generating human retinal progenitors from embryonic stem cells |
| KR20150142061A (ko) | 2006-05-03 | 2015-12-21 | 오카타 세라퓨틱스, 인크. | 배아 줄기 세포 및 배-유도 세포의 유도 |
| EP2128244A4 (en) * | 2007-01-18 | 2012-05-09 | Riken | PROCESS FOR INDUCTION / DIFFERENTIATION TO A PHOTOREZEPTORZELLE |
| EP3190178A1 (en) | 2007-02-23 | 2017-07-12 | Astellas Institute for Regenerative Medicine | Highly efficient methods for reprogramming differentiated cells and for generating animals and embryonic stem cells from reprogrammed cells |
| CN101688178B (zh) * | 2007-04-18 | 2013-12-04 | 哈达锡特医学研究服务及发展有限公司 | 干细胞衍生的视网膜色素上皮细胞 |
| WO2008137115A1 (en) | 2007-05-03 | 2008-11-13 | The Brigham And Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
| US8574567B2 (en) | 2007-05-03 | 2013-11-05 | The Brigham And Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
| US20090028831A1 (en) * | 2007-07-23 | 2009-01-29 | University Of Kentucky Research Foundation | Stem cell regulator, compositions and methods of use |
| DK2209888T3 (da) * | 2007-10-12 | 2020-01-20 | Astellas Inst For Regenerative Medicine | Forbedrede fremgangsmåder til fremstilling af rpe-celler og sammensætninger af rpe-celler |
| AU2015201435B2 (en) * | 2007-10-12 | 2017-02-02 | Astellas Institute For Regenerative Medicine | Improved methods of producing RPE cells and compositions of RPE cells |
| WO2009132156A1 (en) * | 2008-04-22 | 2009-10-29 | Regenerative Research Foundation | Retinal pigment epithelial stem cells |
| CA3066806C (en) | 2009-08-24 | 2023-03-07 | David M. Gamm | Substantially pure human retinal progenitor, forebrain progenitor, and retinal pigment epithelium cell cultures and methods of making the same |
| WO2011063005A2 (en) | 2009-11-17 | 2011-05-26 | Advanced Cell Technology, Inc. | Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells |
| EP3549617B1 (en) | 2010-07-12 | 2023-09-13 | University of Southern California | Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same |
| WO2012012803A2 (en) | 2010-07-23 | 2012-01-26 | Advanced Cell Technology, Inc. | Methods for detection of rare subpopulations of cells and highly purified compositions of cells |
| JP2012231786A (ja) * | 2011-04-18 | 2012-11-29 | Kyushu Univ | 標的遺伝子の発現変化による食品機能成分及び医薬品感受性評価方法 |
| WO2012149468A2 (en) | 2011-04-29 | 2012-11-01 | University Of Southern California | Instruments and methods for the implantation of cell-seeded substrates |
| US8877489B2 (en) | 2011-12-05 | 2014-11-04 | California Institute Of Technology | Ultrathin parylene-C semipermeable membranes for biomedical applications |
| EP2707479B1 (en) | 2011-05-13 | 2018-01-10 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Use of zscan4 and zscan4-dependent genes for direct reprogramming of somatic cells |
| KR101972610B1 (ko) | 2011-05-18 | 2019-04-25 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 망막 질환을 치료하기 위한 조성물 및 방법 |
| WO2013015835A1 (en) | 2011-07-22 | 2013-01-31 | Seven Networks, Inc. | Mobile application traffic optimization |
| CN103007355B (zh) * | 2011-09-20 | 2014-08-13 | 同济大学 | 一种水凝胶-纳米纤维膜及其制备方法和用途 |
| WO2013074681A1 (en) * | 2011-11-14 | 2013-05-23 | Advanced Cell Technology, Inc. | Pharmaceutical preparations of human rpe cells and uses thereof |
| US8961956B2 (en) | 2011-11-30 | 2015-02-24 | Ocata Therapeutics, Inc. | Mesenchymal stromal cells and uses related thereto |
| TWI698242B (zh) | 2011-11-30 | 2020-07-11 | 安斯泰來再生醫藥協會 | 利用血管母細胞產生間葉基質細胞之方法 |
| US9248013B2 (en) | 2011-12-05 | 2016-02-02 | California Institute Of Technology | 3-Dimensional parylene scaffold cage |
| EP2814947B1 (en) * | 2012-02-17 | 2018-11-21 | Schepens Eye Research Institute | Phenotype profile of human retinal progenitor cells |
| US10519422B2 (en) | 2012-02-29 | 2019-12-31 | Riken | Method of producing human retinal pigment epithelial cells |
| US9745551B2 (en) | 2012-07-12 | 2017-08-29 | Imstem Biotechnology, Inc. | Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof |
| CA2882802C (en) * | 2012-08-24 | 2021-07-06 | Riken | Method for producing retinal pigment epithelial cell sheet |
| CA2906815A1 (en) * | 2013-03-15 | 2014-09-18 | Ocata Therapeutics, Inc. | Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells |
| US11241460B2 (en) | 2013-03-15 | 2022-02-08 | Astellas Institute For Regenerative Medicine | Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells |
| WO2014157257A1 (ja) * | 2013-03-25 | 2014-10-02 | 公益財団法人先端医療振興財団 | 細胞の選別方法 |
| EP2796545A1 (en) * | 2013-04-26 | 2014-10-29 | Université Pierre et Marie Curie (Paris 6) | Methods for obtaining retinal progenitors, retinal pigmented epithelial cells and neural retinal cells |
| MX2016006915A (es) | 2013-11-27 | 2017-01-23 | Kyoto Prefectural Public Univ Corp | Aplicacion de laminina a cultivo de celulas endoteliales de la cornea. |
| CN105814194A (zh) | 2013-12-11 | 2016-07-27 | 辉瑞有限公司 | 产生视网膜色素上皮细胞的方法 |
| JP6770435B2 (ja) * | 2014-10-31 | 2020-10-14 | 京都府公立大学法人 | ラミニンによる網膜および神経の新規治療 |
| EP3213762B1 (en) | 2014-10-31 | 2023-11-29 | Kyoto Prefectural Public University Corporation | Novel treatment of cornea using laminin |
| CN118995872A (zh) | 2015-03-23 | 2024-11-22 | 安斯泰来再生医药协会 | 改进的人视网膜色素（rpe）细胞和感光祖细胞的效能测定 |
| KR102651291B1 (ko) | 2015-08-18 | 2024-03-26 | 아스텔라스 인스티튜트 포 리제너러티브 메디슨 | 임상 제제 |
| CA2997528C (en) | 2015-09-08 | 2024-02-13 | Sumitomo Dainippon Pharma Co., Ltd. | Method for producing retinal pigment epithelial cells |
| AU2016321170B2 (en) | 2015-09-08 | 2022-09-01 | Fujifilm Cellular Dynamics | Method for reproducible differentiation of clinical-grade retinal pigment epithelium cells |
| EP4001402A1 (en) | 2015-09-08 | 2022-05-25 | FUJIFILM Cellular Dynamics, Inc. | Macs-based purification of stem cell-derived retinal pigment epithelium |
| ES2862676T3 (es) | 2015-10-20 | 2021-10-07 | Fujifilm Cellular Dynamics Inc | Producción de células precursoras hematopoyéticas multilinaje mediante programación genética |
| CN106609263B (zh) * | 2015-10-22 | 2020-04-07 | 同济大学 | 高效诱导多能干细胞向视网膜色素上皮细胞分化的方法 |
| CN106609256B (zh) * | 2015-10-22 | 2020-04-07 | 同济大学 | 体外诱导人胚胎干细胞分化为视网膜色素上皮细胞的方法 |
| CN106609257B (zh) * | 2015-10-22 | 2020-04-10 | 同济大学 | 高效分离体外诱导的rpe细胞和rpc的方法 |
| CN106609255B (zh) * | 2015-10-22 | 2019-11-05 | 同济大学 | 含pj34和视网膜色素上皮细胞的细胞悬液及其应用 |
| CN106282096A (zh) * | 2016-10-19 | 2017-01-04 | 江苏艾尔康生物医药科技有限公司 | 一种人类视网膜色素上皮细胞层的分离培养方法 |
| JP7007686B2 (ja) | 2017-03-08 | 2022-01-25 | 大日本住友製薬株式会社 | 網膜色素上皮細胞の製造方法 |
| KR20200031559A (ko) * | 2017-03-16 | 2020-03-24 | 리니지 셀 테라퓨틱스, 인크. | 망막 질환 요법의 치료 효과를 측정하는 방법 |
| AU2018254442B2 (en) | 2017-04-18 | 2024-03-28 | FUJIFILM Cellular Dynamics, Inc. | Antigen-specific immune effector cells |
| EP3683304A4 (en) * | 2017-09-14 | 2021-06-09 | Riken | METHOD OF REINFORCEMENT OF PIPE PHOTO RECEPTORS OR ROD PHOTO RECEPTORS WITH A DORSALIZATION SIGNAL TRANSMITTER OR VENTRALIZATION SIGNAL TRANSMITTER |
| CA3082080A1 (en) | 2017-11-15 | 2019-05-23 | Friedrich Miescher Institute For Biomedical Research | Primate retinal pigment epithelium cell-specific promoter |
| CN108029638B (zh) * | 2017-12-04 | 2020-04-21 | 四川省人民医院 | 一种视网膜色素变性疾病动物模型的构建方法及应用 |
| CA3093074A1 (en) * | 2018-03-12 | 2019-09-19 | Nxcell Inc. | Method for generating multiple cellular products from single pluripotent cell source |
| JP7553924B2 (ja) | 2019-04-26 | 2024-09-19 | 国立研究開発法人理化学研究所 | 神経網膜と網膜色素上皮細胞とハイドロゲルとを含む複合体及びその製造方法 |
| BR112022006644A2 (pt) * | 2019-10-30 | 2022-07-12 | Astellas Inst For Regenerative Medicine | Métodos para a produção de células epiteliais de pigmento da retina |
| RU2730937C1 (ru) * | 2019-11-01 | 2020-08-26 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ГБ им. Гельмгольца" Миндрава России) | Способ трансплантации клеток ретинального пигментного эпителия (РПЭ), дифференцированных из индуцированных плюрипотентных стволовых клеток человека, при атрофии ретинального пигментного эпителия |
| EP4306634A4 (en) | 2021-03-09 | 2025-03-26 | Riken | METHOD FOR PRODUCING HYPOIMMUNOGENIC RETINAL PIGMENT EPITHELIAL CELLS |
| CA3238664A1 (en) | 2021-11-19 | 2023-05-25 | Riken | Production method for sheet-like retinal tissue |
| CA3254454A1 (en) | 2022-03-16 | 2025-03-04 | Racthera Co., Ltd. | METHOD OF TRANSPLANTATION |
| WO2023201361A1 (en) | 2022-04-15 | 2023-10-19 | Aspen Neuroscience, Inc. | Methods of classifying the differentiation state of cells and related compositions of differentiated cells |
| JPWO2024172043A1 (enExample) | 2023-02-14 | 2024-08-22 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3490447B2 (ja) | 1993-04-30 | 2004-01-26 | フォトジェネシス インコーポレイテッド | 網膜色素上皮移植 |
| US6878544B2 (en) | 1996-04-19 | 2005-04-12 | Neurotech Sa | Retinal cell lines with extended life-span and their applications |
| US20040086494A1 (en) | 1996-10-07 | 2004-05-06 | John Constance Mary | Immune privileged cells for delivery of proteins and peptides |
| JP2001508302A (ja) | 1997-01-10 | 2001-06-26 | ライフ テクノロジーズ，インコーポレイテッド | 胚性幹細胞血清置換 |
| US6331406B1 (en) * | 1997-03-31 | 2001-12-18 | The John Hopkins University School Of Medicine | Human enbryonic germ cell and methods of use |
| CA2317115A1 (en) | 1998-01-02 | 1999-07-15 | Titan Pharmaceuticals, Inc. | Use of pigmented retinal epithelial cells for creation of an immune privilege site |
| EP1066368A4 (en) | 1998-03-02 | 2002-08-21 | Compucyte Corp | SELECTIVE CELL ANALYSIS |
| US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
| US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
| IL149175A0 (en) | 1999-10-28 | 2002-11-10 | Univ Massachusetts | Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues |
| JP3454206B2 (ja) * | 1999-11-10 | 2003-10-06 | 三菱電機株式会社 | 雑音抑圧装置及び雑音抑圧方法 |
| EP1248517A2 (en) | 2000-01-07 | 2002-10-16 | Oregon Health and Science University | Clonal propagation of primate offspring by embryo splitting |
| US6602711B1 (en) * | 2000-02-21 | 2003-08-05 | Wisconsin Alumni Research Foundation | Method of making embryoid bodies from primate embryonic stem cells |
| US20030084471A1 (en) * | 2000-03-16 | 2003-05-01 | David Beach | Methods and compositions for RNA interference |
| US6458589B1 (en) | 2000-04-27 | 2002-10-01 | Geron Corporation | Hepatocyte lineage cells derived from pluripotent stem cells |
| WO2002016620A2 (en) | 2000-08-19 | 2002-02-28 | Axordia Limited | Modulation of stem cell differentiation |
| US6576464B2 (en) | 2000-11-27 | 2003-06-10 | Geron Corporation | Methods for providing differentiated stem cells |
| AU3649502A (en) | 2000-11-29 | 2002-06-11 | Oculex Pharm Inc | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
| DE10108412B4 (de) * | 2001-02-21 | 2006-03-09 | Cevec Pharmaceuticals Gmbh | Pigmentepithelzelle des Auges, ihre Herstellung und Verwendung in der Therapie einer Augen- oder Nervenerkrankung |
| EP1393066A4 (en) | 2001-05-15 | 2006-01-25 | Rappaport Family Inst For Res | INSULIN-PRODUCING CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS |
| KR20040022448A (ko) | 2001-07-12 | 2004-03-12 | 제론 코포레이션 | 인간 다분화능 줄기 세포로부터 제조된 심근 세포 계통의세포 |
| AU2002360424A1 (en) * | 2001-11-26 | 2003-06-10 | Advanced Cell Technology, Inc. | Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells |
| ATE526041T1 (de) | 2001-12-11 | 2011-10-15 | Fibrogen Inc | Verfahren zur hemmung okularer vorgänge |
| EP1495120B1 (en) | 2002-04-18 | 2012-10-10 | Acuity Pharmaceuticals, Inc | Means and methods for the specific modulation of target genes in the eye |
| US7422736B2 (en) | 2002-07-26 | 2008-09-09 | Food Industry Research And Development Institute | Somatic pluripotent cells |
| WO2004033635A2 (en) | 2002-10-04 | 2004-04-22 | Tissuetech, Inc. | Retinal pigment epithelial cell cultures on amniotic membrane and transplantation |
| JP4348706B2 (ja) * | 2002-10-08 | 2009-10-21 | 日本電気株式会社 | アレイ装置および携帯端末 |
| JP2006509537A (ja) | 2002-11-14 | 2006-03-23 | エシコン・エンド−サージェリィ・インコーポレイテッド | 組織細胞を検出するための方法および機器 |
| JP2007501407A (ja) | 2003-03-03 | 2007-01-25 | 長岡実業株式会社 | 多様な細胞タイプの検出および定量に使用される方法および装置並びにこれを行うための光バイオディスクの使用 |
| EP2929782A1 (en) | 2004-01-23 | 2015-10-14 | Ocata Therapeutics, Inc. | Improved modalities for the treatment of degenerative diseases of the retina |
| US7794704B2 (en) | 2004-01-23 | 2010-09-14 | Advanced Cell Technology, Inc. | Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration |
| US7838727B2 (en) | 2004-11-04 | 2010-11-23 | Advanced Cell Technology, Inc. | Derivation of embryonic stem cells |
| CN102220280A (zh) | 2005-02-11 | 2011-10-19 | 新加坡科技研究局 | 增殖干细胞的方法 |
| KR100832592B1 (ko) | 2006-08-17 | 2008-05-27 | 박현숙 | 폴리머 막을 이용한 줄기세포와 피더세포의 공배양방법 |
| CN101688178B (zh) | 2007-04-18 | 2013-12-04 | 哈达锡特医学研究服务及发展有限公司 | 干细胞衍生的视网膜色素上皮细胞 |
| JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
| DK2209888T3 (da) | 2007-10-12 | 2020-01-20 | Astellas Inst For Regenerative Medicine | Forbedrede fremgangsmåder til fremstilling af rpe-celler og sammensætninger af rpe-celler |
| HU0700675D0 (en) | 2007-10-15 | 2007-12-28 | Mta Tamogatott Kutatohelyek Ir | Method for monitoring stem cell differentiation |
| US20090233324A1 (en) | 2008-03-11 | 2009-09-17 | Kopf-Sill Anne R | Methods for Diagnosing Cancer Using Samples Collected From A Central Vein Location or an Arterial Location |
| US8652123B2 (en) | 2008-09-02 | 2014-02-18 | Geoffrey C. GURTNER | Methods and devices for improving the appearance of tissue |
| WO2011063005A2 (en) | 2009-11-17 | 2011-05-26 | Advanced Cell Technology, Inc. | Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells |
| WO2012012803A2 (en) | 2010-07-23 | 2012-01-26 | Advanced Cell Technology, Inc. | Methods for detection of rare subpopulations of cells and highly purified compositions of cells |
| JP6200883B2 (ja) | 2011-04-29 | 2017-09-20 | ユニヴァーシティー オブ サザン カリフォルニア | ポリマー基質上の幹細胞由来網膜色素上皮細胞の低温保存方法 |
| WO2013074681A1 (en) | 2011-11-14 | 2013-05-23 | Advanced Cell Technology, Inc. | Pharmaceutical preparations of human rpe cells and uses thereof |
| US9850463B2 (en) | 2012-02-01 | 2017-12-26 | The Regents Of The University Of California | Methods of culturing retinal pigmented epithelium cells, including xeno-free production, RPE enrichment, and cryopreservation |
| ES2688019T3 (es) | 2012-06-05 | 2018-10-30 | The Regents Of The University Of California | Métodos y composiciones para la producción acelerada de células epiteliales pigmentadas retinianas a partir de células pluripotentes |
-
2005
- 2005-01-24 EP EP15248003.4A patent/EP2929782A1/en not_active Ceased
- 2005-01-24 AU AU2005207042A patent/AU2005207042B2/en not_active Expired
- 2005-01-24 JP JP2006551392A patent/JP2007522131A/ja active Pending
- 2005-01-24 KR KR1020127008183A patent/KR101398356B1/ko not_active Expired - Lifetime
- 2005-01-24 SG SG10201912182UA patent/SG10201912182UA/en unknown
- 2005-01-24 SG SG2013009170A patent/SG188122A1/en unknown
- 2005-01-24 CN CN201410645051.XA patent/CN104434979A/zh active Pending
- 2005-01-24 CN CN2005800073590A patent/CN1968608B/zh not_active Expired - Lifetime
- 2005-01-24 SG SG10201606441SA patent/SG10201606441SA/en unknown
- 2005-01-24 CA CA2555370A patent/CA2555370C/en not_active Expired - Lifetime
- 2005-01-24 EP EP11183611A patent/EP2438815A3/en not_active Withdrawn
- 2005-01-24 SG SG200905546-8A patent/SG155236A1/en unknown
- 2005-01-24 EP EP23176538.9A patent/EP4248752A3/en not_active Withdrawn
- 2005-01-24 CA CA2937099A patent/CA2937099A1/en active Pending
- 2005-01-24 EP EP23176537.1A patent/EP4269561A3/en not_active Withdrawn
- 2005-01-24 WO PCT/US2005/002273 patent/WO2005070011A2/en not_active Ceased
- 2005-01-24 ES ES11183613T patent/ES2721174T3/es not_active Expired - Lifetime
- 2005-01-24 KR KR1020067016837A patent/KR101258292B1/ko not_active Expired - Lifetime
- 2005-01-24 CN CN201110132307.3A patent/CN102204930B/zh not_active Expired - Lifetime
- 2005-01-24 EP EP22188897.7A patent/EP4248751A3/en active Pending
- 2005-01-24 KR KR1020137002345A patent/KR20130025953A/ko not_active Ceased
- 2005-01-24 EP EP11183613.6A patent/EP2438816B1/en not_active Expired - Lifetime
- 2005-01-24 EP EP11183610A patent/EP2438814A3/en not_active Withdrawn
- 2005-01-24 EP EP05711960A patent/EP1708575A4/en not_active Withdrawn
- 2005-01-24 NZ NZ548929A patent/NZ548929A/en not_active IP Right Cessation
- 2005-01-24 BR BRPI0507074-0A patent/BRPI0507074A/pt not_active Application Discontinuation
- 2005-01-24 MX MX2015009311A patent/MX375061B/es unknown
- 2005-01-24 MX MX2014001634A patent/MX375065B/es unknown
- 2005-07-20 US US11/186,720 patent/US7736896B2/en active Active
-
2006
- 2006-07-20 IL IL177015A patent/IL177015B/en active IP Right Grant
- 2006-07-21 MX MX2011006096A patent/MX343606B/es unknown
- 2006-07-21 US US11/490,953 patent/US7795025B2/en active Active
- 2006-07-21 MX MX2020009456A patent/MX2020009456A/es unknown
-
2007
- 2007-04-04 HK HK16104134.1A patent/HK1216068A1/en unknown
-
2010
- 2010-05-18 US US12/781,929 patent/US9040770B2/en active Active
- 2010-08-17 US US12/857,866 patent/US9649340B2/en not_active Expired - Lifetime
- 2010-12-09 AU AU2010249263A patent/AU2010249263B2/en not_active Expired
-
2012
- 2012-02-27 JP JP2012040491A patent/JP2012148085A/ja active Pending
-
2013
- 2013-03-21 AU AU2013201791A patent/AU2013201791B2/en not_active Expired
-
2014
- 2014-01-30 JP JP2014016135A patent/JP2014079650A/ja not_active Ceased
-
2015
- 2015-02-12 JP JP2015025500A patent/JP2015096556A/ja not_active Ceased
- 2015-04-21 US US14/692,191 patent/US9730962B2/en not_active Expired - Fee Related
- 2015-08-31 HK HK15108469.8A patent/HK1207821A1/xx unknown
-
2016
- 2016-08-02 JP JP2016152133A patent/JP2016195862A/ja not_active Withdrawn
- 2016-11-15 AU AU2016259323A patent/AU2016259323B2/en not_active Expired
-
2017
- 2017-07-18 US US15/653,472 patent/US20180064761A1/en not_active Abandoned
- 2017-12-28 JP JP2017254812A patent/JP2018086274A/ja not_active Ceased
-
2019
- 2019-01-25 AU AU2019200513A patent/AU2019200513A1/en not_active Abandoned
- 2019-06-05 IL IL267126A patent/IL267126B/en unknown
- 2019-09-19 JP JP2019170249A patent/JP2019217356A/ja active Pending
-
2020
- 2020-06-18 JP JP2020105536A patent/JP2020146575A/ja not_active Ceased
-
2021
- 2021-01-29 AU AU2021200601A patent/AU2021200601A1/en not_active Abandoned
-
2022
- 2022-03-07 IL IL291162A patent/IL291162A/en unknown
- 2022-08-03 JP JP2022124147A patent/JP2022153630A/ja active Pending
-
2024
- 2024-01-22 JP JP2024007584A patent/JP2024038460A/ja active Pending
Non-Patent Citations (1)
| Title |
|---|
| REUBINOFF BENJAMIN E ET AL.《Embryonic stem cell lines from human blastocysts: Somatic differentiation in vitro.》.《nature biotechnology》.2000,第18卷(第4期), * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102204930B (zh) | 用于治疗视网膜变性病的改良模式 | |
| US20210102164A1 (en) | Modalities for the treatment of degenerative diseases of the retina | |
| JP2015091272A5 (enExample) | ||
| US20240174978A1 (en) | Modalities for the treatment of degenerative diseases of the retina | |
| HK40097391A (en) | Improved modalities for the treatment of degenerative diseases of the retina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1162931 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: OCATA THERAPEUTICS, INC. Free format text: FORMER NAME: ADVANCED CELL TECHNOLOGY, INC. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: Massachusetts, USA Patentee after: Ocata Treatment Co. Address before: Massachusetts, USA Patentee before: Advanced Cell Technology, Inc. |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1162931 Country of ref document: HK |
|
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: Massachusetts, USA Patentee after: OCATA THERAPEUTICS, Inc. Address before: Massachusetts, USA Patentee before: Ocata Treatment Co. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20141203 |
|
| CX01 | Expiry of patent term |